Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Histiocytoma, Malignant Fibrous

• Palbociclib and Pembrolizumab in Undifferentiated Pleomorphic Sarcoma (UPS)
• Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
• A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma
• Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas
• Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
• A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
• ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma
• Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
• A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg
• Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
• A Study of LY3435151 in Participants With Solid Tumors
• Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients
• Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma
• A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
• Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
• Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall
• LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
• Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma
• Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
• Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma
• Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
• Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
• Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
• ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
• Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
• Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
• Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
• Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
• Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
• Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
• A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma
• AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
• Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
• Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery
• Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
• Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
• Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma
• Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma
• Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
• Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
• Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma
• Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma